Edward Nash analyst CANACCORD

Currently out of the existing stock ratings of Edward Nash, 248 are a BUY (93.23%), 18 are a HOLD (6.77%).

Edward Nash

Work Performance Price Targets & Ratings Chart

Analyst Edward Nash, currently employed at CANACCORD, carries an average stock price target met ratio of 50.66% that have a potential upside of 60.52% achieved within 310 days.

Edward Nash’s has documented 527 price targets and ratings displayed on 56 stocks. The coverage is on Healthcare, Technology, Consumer Defensive, Energy sectors.

Most recent stock forecast was given on IVA, Inventiva Sa.

Wall Street Analyst Edward Nash

Analyst best performing recommendations are on BLUE (BLUEBIRD BIO).
The best stock recommendation documented was for BLUE (BLUEBIRD BIO) at 6/6/2017. The price target of $1398.96 was fulfilled within 1 day with a profit of $127.57 (10.03%) receiving and performance score of 100.34.

Average potential price target upside

AKAO Achaogen AKRO Akero Therapeutics BLUE Bluebird bio CRDL Cardiol Therapeutics GLMD Galmed Pharmaceuticals Ltd ICPT Intercept Pharmaceuticals MDGL Madrigal Pharmaceuticals MTCR Metacrine ORMP Oramed Pharmaceuticals SRPT Sarepta Therapeutics THTX Theratechnologies VRNA Verona Pharma PLC ADR ITCI Intracellular Th ONCE Spark Therapeutics RARE Ultragenyx TVTX Travere Therapeutics BMRN Biomarin Pharmaceutical CCXI ChemoCentryx DRNA Dicerna Pharmaceuticals OBSV ObsEva SA OTIC Otonomy TTPH Tetraphase Pharmaceuticals CPRX Catalyst Pharmaceuticals SAGE Sage Therapeutic VTYX Ventyx Biosciences AMYT Amryt Pharma Holdings Ltd ABEO Abeona Therapeutics ZFGN Zafgen CORT Corcept Therapeutics DICE Dice Molecules Holdings LLC RANI Rani Therapeutics Holdings NBRV Nabriva Therapeutics AG IVA Inventiva Sa MORF Morphic PLRX Pliant Therapeutics RZLT Rezolute CBAY Cymabay Therapeu CLDX Celldex Therapeutics LRMR Larimar Therapeutics SMMT Summit Therapeutics PLC VKTX Viking Therapeutics WVE Wave Life Sciences Ltd APGE Apogee Therapeutics, Common Stock ADVM Adverum Biotechnologies AKR Acadia Realty Trust ANAB AnaptysBio ARGX argenx NV ADR CNAT Conatus Pharmaceuticals IT Gartner MO Altria Group QURE Uniqure NV SGMT Sagimet Biosciences Series A Common Stock TH Target Hospitality Corp CNTB Connect Biopharma Holdings Ltd KNSA Kiniksa Pharmaceuticals Ltd KYMR Kymera Therapeutics

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Buy Since 16-Mar-2017

$3

$2.89 (2627.27%)

7 years 10 months 19 days ago
(13-Nov-2018)

0/3 (0%)

$1.07 (55.44%)

Buy Since 06-Mar-2017

$3

$2.89 (2627.27%)

$22

7 years 10 months 20 days ago
(12-Nov-2018)

0/3 (0%)

$1 (50.00%)

Hold Since 12-Nov-2018

$3

$2.89 (2627.27%)

$19

7 years 10 months 20 days ago
(12-Nov-2018)

0/7 (0%)

$1 (50.00%)

$3

$2.89 (2627.27%)

$22

7 years 10 months 23 days ago
(09-Nov-2018)

1/6 (16.67%)

$0.75 (33.33%)

31

Buy Since 09-Nov-2018

$8

7 years 10 months 23 days ago
(09-Nov-2018)

1/4 (25%)

$4.75 (146.15%)

41

Show more analysts

Please expand the browser size to see the chart

Which stock is Edward Nash most bullish on?

Potential upside of $78.44 has been obtained for VKTX (VIKING THERAPEUTICS)

Which stock is Edward Nash most reserved on?

Potential downside of $0.04 has been obtained for APGE (APOGEE THERAPEUTICS, COMMON STOCK)

What Year was the first public recommendation made by Edward Nash?

On 2014
✖

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?